Keating Gillian M, Scott Lesley J
Adis International Limited, Auckland, New Zealand.
Drugs. 2004;64(20):2347-77. doi: 10.2165/00003495-200464200-00006.
Moxifloxacin (Avelox) is a fluoroquinolone antibacterial with a methoxy group in the C-8 position and a bulky C-7 side chain. Moxifloxacin is approved for use in the treatment of acute exacerbations of chronic bronchitis (AECB), community-acquired pneumonia (CAP), acute bacterial sinusitis and uncomplicated skin and skin structure infections (approved indications may differ between countries). Moxifloxacin has a broad spectrum of antibacterial activity, including activity against penicillin-resistant Streptococcus pneumoniae. It achieves good tissue penetration and has a convenient once-daily administration schedule, as well as being available in both intravenous and oral formulations in some markets. Moxifloxacin has good efficacy in the treatment of patients with AECB, CAP, acute bacterial sinusitis and uncomplicated skin and skin structure infections, and is generally well tolerated. Thus, moxifloxacin is an important option in the treatment of bacterial infections.
莫西沙星（拜复乐）是一种氟喹诺酮类抗菌药物，在C-8位有一个甲氧基和一个庞大的C-7侧链。莫西沙星被批准用于治疗慢性支气管炎急性加重（AECB）、社区获得性肺炎（CAP）、急性细菌性鼻窦炎以及非复杂性皮肤和皮肤结构感染（不同国家的批准适应症可能有所不同）。莫西沙星具有广泛的抗菌活性，包括对耐青霉素肺炎链球菌的活性。它具有良好的组织穿透力，给药方案方便，每日一次，并且在某些市场有静脉和口服两种剂型。莫西沙星在治疗AECB、CAP、急性细菌性鼻窦炎和非复杂性皮肤和皮肤结构感染患者方面疗效良好，且一般耐受性良好。因此，莫西沙星是治疗细菌感染的重要选择。
